FT Global Pharma and Biotech Summit 2026

The Global Pharma and Biotech Summit is the Financial Times' annual London gathering for the leaders shaping the next phase of the life sciences industry. Under the 2026 theme "Rewriting the rules of growth, access and innovation", two days of sessions in person and online look at Europe's competitiveness, the US post-Most Favored Nation pricing regime, new uses of AI, direct access to medicines, China's influence and the future of the NHS, with a focus on turning scientific momentum into commercial success and better patient outcomes.

Key themes

The programme is built around five pressures on pharma operating models.

• Geopolitical and economic disruption, including US–China decoupling
• The rise of new pharma powers in India and China
• Regulation of emerging technologies, AI and real-world evidence
• Drug pricing and reimbursement pressures
• Patient empowerment and digital health

Who attends

Senior leaders from pharma, biotech, government, investment and the wider life sciences ecosystem. The organiser expects 350+ attendees, 60+ speakers and FT journalists, and 260+ companies from 20+ countries.

Networking

In-person delegates get networking breaks, lunches and drinks across both days, direct access to speakers and the FT Live networking app to arrange meetings in advance.

Tickets & passes

• Pharma & Biotech Pass — GBP 2,499: Plus VAT; in-person sessions and networking drinks
• Supplier Pass — GBP 3,499: Plus VAT; in-person sessions and networking drinks